MK-7264
Total Payments
$14.3M
Transactions
4,939
Doctors
79
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.7M | 1,078 | 15 |
| 2019 | $6.9M | 2,220 | 32 |
| 2018 | $3.6M | 1,562 | 59 |
| 2017 | $988,249 | 79 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.0M | 4,318 | 98.0% |
| Consulting Fee | $212,589 | 116 | 1.5% |
| Travel and Lodging | $58,775 | 233 | 0.4% |
| Food and Beverage | $12,553 | 272 | 0.1% |
Payments by Type
Research
$14.0M
4,318 transactions
General
$283,917
621 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | Merck Sharp & Dohme Corporation | $4.3M | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN027 | Merck Sharp & Dohme Corporation | $2.4M | 0 |
| A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | Merck Sharp & Dohme Corporation | $1.8M | 1 |
| A Randomized Double Blind Clinical Trial to Evaluate the Effects of MK-7264 in Participants with Obstructive Sleep Apnea | Merck Sharp & Dohme Corporation | $1.4M | 0 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN030 | Merck Sharp & Dohme Corporation | $581,544 | 0 |
| A Study to Characterize the Pharmacokinetic Performance of Different Formulations of MK-7264 in Healthy Adult Subjects under Fed and Fasted Conditions. | Merck Sharp & Dohme Corporation | $381,031 | 0 |
| A Two-Period Fixed Sequence Study to Evaluate the Effects of Multiple-Dose Gefapixant MK-7264 on the Single-Dose Pharmacokinetics of Pitavastatin in Healthy Adult Participants. | Merck Sharp & Dohme Corporation | $355,645 | 0 |
| An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264 | Merck Sharp & Dohme Corporation | $336,590 | 0 |
| A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence | Merck Sharp & Dohme Corporation | $329,479 | 0 |
| An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of a Formulation of MK-7264 in Healthy Adult Subjects | Merck Sharp & Dohme Corporation | $274,021 | 0 |
| A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough | Merck Sharp & Dohme Corporation | $253,677 | 0 |
| An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of MK-7264 in Healthy Adult Male Subjects | Merck Sharp & Dohme Corporation | $252,707 | 0 |
| An Open-Label, Two-Part, Two-Period Crossover Study to Determine Bioequivalence Between Gefapixant MK-7264 F04A and F04B Formulations at 45 mg and 15 mg Single Doses in Healthy Participants | Merck Sharp & Dohme Corporation | $234,423 | 0 |
| Kaiser - Database Cough Study | Merck Sharp & Dohme Corporation | $231,766 | 0 |
| A two-period fixed sequence study to evaluate the effects of pyrimethamine, a potent inhibitor of MATE1,2K, on the pharmacokinetics of MK-7264 in healthy adults | Merck Sharp & Dohme Corporation | $221,262 | 0 |
| Investigation of Pathomechanisms Of Chronic Cough Using In Vitro Approaches | Merck Sharp & Dohme Corporation | $126,750 | 0 |
| Ph 2B 12wk Chronic Cough | Merck Sharp & Dohme Corporation | $94,402 | 0 |
| Analyzing Patients with Unexplained Chronic Cough in the Primary Care Setting | Merck Sharp & Dohme Corporation | $76,163 | 0 |
| A Phase 3b Randomized Double-blind, Placebo Controlled, MulticenterStudy to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence | Merck Sharp & Dohme Corporation | $60,200 | 0 |
| A Study to Evaluate the Palatability of Two Formulations ofMK-7264 in Healthy Adult Subjects. | Merck Sharp & Dohme Corporation | $48,884 | 0 |
Top Doctors Receiving Payments for MK-7264 — Page 4
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $14.3M
- Total Doctors 79
- Transactions 4,939
About MK-7264
MK-7264 is a drug associated with $14.3M in payments to 79 healthcare providers, recorded across 4,939 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $2.7M was paid across 1,078 transactions to 15 doctors.
The most common payment nature for MK-7264 is "Unspecified" ($14.0M, 98.0% of total).
MK-7264 is associated with 20 research studies, including "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030" ($4.3M).